MATTERHORN supports the global adoption of perioperative durvalumab plus FLOT as a new standard for patients with localized gastric and gastroesophageal junction adenocarcinoma,” said Yelena Y.

AstraZeneca, in collaboration with Daiichi Sankyo, is conducting a Phase III clinical study titled A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator’s Choice of ...

In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...

Q2 2025 Earnings Call Transcript August 8, 2025 Operator: Welcome to the Lisata Therapeutics Second Quarter 2025 Financial ...

Immmunotherapy-based treatments demonstrate effectiveness and safety profiles consistent with clinical trials in real-world setting.

Australians with Parkinson's disease, neuroblastoma, endometrial cancer, cystic fibrosis and melanoma will have access to new and expanded medicines ...

Detailed price information for Replimune Group Inc (REPL-Q) from The Globe and Mail including charting and trades.

In the ongoing Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer, fewer deaths have been observed than originally projected. We believe th ...

With its domination of the indication- and brand-specific analyses, it should come as no surprise that AstraZeneca led the ...

In August 2025, Seagen announced a studies how well tucatinib works for solid tumors that make either more HER2 or a ...

AstraZeneca PLC thrives with $54B revenue and 14 blockbusters in 2024, fueled by oncology and rare disease growth. Click for ...

In August 2025, Bristol-Myers Squibb announced a study is to evaluate the safety and effectiveness of triplet therapy of ...